Cargando…

Acute molecular effects of pressure‐controlled intermittent coronary sinus occlusion in patients with advanced heart failure

AIMS: Cardiac repair has steered clinical attention and remains an unmet need, because available regenerative therapies lack robust mechanistic evidence. Pressure‐controlled intermittent coronary sinus occlusion (PICSO), known to induce angiogenetic and vasoactive molecules as well as to reduce regi...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohl, Werner, Spitzer, Ernest, Mader, Robert M., Wagh, Vilas, Nguemo, Filomain, Milasinovic, Dejan, Jusić, Alem, Khazen, Cesar, Szodorai, Edit, Birkenberg, Beatrice, Lubec, Gert, Hescheler, Juergen, Serruys, Patrick W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6301157/
https://www.ncbi.nlm.nih.gov/pubmed/30230713
http://dx.doi.org/10.1002/ehf2.12354
_version_ 1783381789218177024
author Mohl, Werner
Spitzer, Ernest
Mader, Robert M.
Wagh, Vilas
Nguemo, Filomain
Milasinovic, Dejan
Jusić, Alem
Khazen, Cesar
Szodorai, Edit
Birkenberg, Beatrice
Lubec, Gert
Hescheler, Juergen
Serruys, Patrick W.
author_facet Mohl, Werner
Spitzer, Ernest
Mader, Robert M.
Wagh, Vilas
Nguemo, Filomain
Milasinovic, Dejan
Jusić, Alem
Khazen, Cesar
Szodorai, Edit
Birkenberg, Beatrice
Lubec, Gert
Hescheler, Juergen
Serruys, Patrick W.
author_sort Mohl, Werner
collection PubMed
description AIMS: Cardiac repair has steered clinical attention and remains an unmet need, because available regenerative therapies lack robust mechanistic evidence. Pressure‐controlled intermittent coronary sinus occlusion (PICSO), known to induce angiogenetic and vasoactive molecules as well as to reduce regional ischemia, may activate endogenous regenerative processes in failing myocardium. We aimed to investigate the effects of PICSO in patients with advanced heart failure undergoing cardiac resynchronization therapy. METHODS AND RESULTS: Eight out of 32 patients were treated with PICSO, and the remainder served as controls. After electrode testing including left ventricular leads, PICSO was performed for 20 min. To test immediate molecular responses, in both patient groups, coronary venous blood samples were taken at baseline and after 20 min, the time required for the intervention. Sera were tested for microRNAs and growth factors. To test the ability of up‐regulated soluble factors on cell proliferation and expression of transcription factors [e.g. Krüppel‐like factor 4 (KLF‐4)], sera were co‐cultured with human cardiomyocytes and fibroblasts. As compared with controls, significant differential expression (differences between pre‐values and post‐values in relation to both patient cohorts) of microRNA patterns associated with cardiac development was observed with PICSO. Importantly, miR‐143 (P < 0.048) and miR‐145 (P < 0,047) increased, both targeting a network of transcription factors (including KLF‐4) that promote differentiation and repress proliferation of vascular smooth muscle cells. Additionally, an increase of miR‐19b (P < 0.019) known to alleviate endothelial cell apoptosis was found, whereas disadvantageous miR‐320b (P < 0.023) suspect to impair expression of c‐myc, normally provoking cell cycle re‐entry in post‐mitotic myocytes and miR‐25 (P < 0.023), decreased, a target of anti‐miR application to improve contractility in the failing heart. Co‐cultured post‐PICSO sera significantly increased cellular proliferation both in fibroblasts (P < 0.001) and adult cardiomycytes (P < 0.004) sampled from a transplant recipient as compared with controls. Adult cardiomyocytes showed a seven‐fold increase of the transcription factor KLF‐4 protein when co‐cultured with treated sera as compared with controls. CONCLUSIONS: Here, we show for the first time that PICSO, a trans‐coronary sinus catheter intervention, is associated with an increase in morphogens secreted into cardiac veins, normally present during cardiac development, and a significant induction of cell proliferation. Present findings support the notion that epigenetic modifications, that is, haemodynamic stimuli on venous vascular cells, may reverse myocardial deterioration. Further investigations are needed to decipher the maze of complex interacting molecular pathways in failing myocardium and the potential role of PICSO to reinitiate developmental processes to prevent further myocardial decay eventually reaching clinical significance.
format Online
Article
Text
id pubmed-6301157
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-63011572018-12-31 Acute molecular effects of pressure‐controlled intermittent coronary sinus occlusion in patients with advanced heart failure Mohl, Werner Spitzer, Ernest Mader, Robert M. Wagh, Vilas Nguemo, Filomain Milasinovic, Dejan Jusić, Alem Khazen, Cesar Szodorai, Edit Birkenberg, Beatrice Lubec, Gert Hescheler, Juergen Serruys, Patrick W. ESC Heart Fail Short Communication AIMS: Cardiac repair has steered clinical attention and remains an unmet need, because available regenerative therapies lack robust mechanistic evidence. Pressure‐controlled intermittent coronary sinus occlusion (PICSO), known to induce angiogenetic and vasoactive molecules as well as to reduce regional ischemia, may activate endogenous regenerative processes in failing myocardium. We aimed to investigate the effects of PICSO in patients with advanced heart failure undergoing cardiac resynchronization therapy. METHODS AND RESULTS: Eight out of 32 patients were treated with PICSO, and the remainder served as controls. After electrode testing including left ventricular leads, PICSO was performed for 20 min. To test immediate molecular responses, in both patient groups, coronary venous blood samples were taken at baseline and after 20 min, the time required for the intervention. Sera were tested for microRNAs and growth factors. To test the ability of up‐regulated soluble factors on cell proliferation and expression of transcription factors [e.g. Krüppel‐like factor 4 (KLF‐4)], sera were co‐cultured with human cardiomyocytes and fibroblasts. As compared with controls, significant differential expression (differences between pre‐values and post‐values in relation to both patient cohorts) of microRNA patterns associated with cardiac development was observed with PICSO. Importantly, miR‐143 (P < 0.048) and miR‐145 (P < 0,047) increased, both targeting a network of transcription factors (including KLF‐4) that promote differentiation and repress proliferation of vascular smooth muscle cells. Additionally, an increase of miR‐19b (P < 0.019) known to alleviate endothelial cell apoptosis was found, whereas disadvantageous miR‐320b (P < 0.023) suspect to impair expression of c‐myc, normally provoking cell cycle re‐entry in post‐mitotic myocytes and miR‐25 (P < 0.023), decreased, a target of anti‐miR application to improve contractility in the failing heart. Co‐cultured post‐PICSO sera significantly increased cellular proliferation both in fibroblasts (P < 0.001) and adult cardiomycytes (P < 0.004) sampled from a transplant recipient as compared with controls. Adult cardiomyocytes showed a seven‐fold increase of the transcription factor KLF‐4 protein when co‐cultured with treated sera as compared with controls. CONCLUSIONS: Here, we show for the first time that PICSO, a trans‐coronary sinus catheter intervention, is associated with an increase in morphogens secreted into cardiac veins, normally present during cardiac development, and a significant induction of cell proliferation. Present findings support the notion that epigenetic modifications, that is, haemodynamic stimuli on venous vascular cells, may reverse myocardial deterioration. Further investigations are needed to decipher the maze of complex interacting molecular pathways in failing myocardium and the potential role of PICSO to reinitiate developmental processes to prevent further myocardial decay eventually reaching clinical significance. John Wiley and Sons Inc. 2018-09-19 /pmc/articles/PMC6301157/ /pubmed/30230713 http://dx.doi.org/10.1002/ehf2.12354 Text en © 2018 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Short Communication
Mohl, Werner
Spitzer, Ernest
Mader, Robert M.
Wagh, Vilas
Nguemo, Filomain
Milasinovic, Dejan
Jusić, Alem
Khazen, Cesar
Szodorai, Edit
Birkenberg, Beatrice
Lubec, Gert
Hescheler, Juergen
Serruys, Patrick W.
Acute molecular effects of pressure‐controlled intermittent coronary sinus occlusion in patients with advanced heart failure
title Acute molecular effects of pressure‐controlled intermittent coronary sinus occlusion in patients with advanced heart failure
title_full Acute molecular effects of pressure‐controlled intermittent coronary sinus occlusion in patients with advanced heart failure
title_fullStr Acute molecular effects of pressure‐controlled intermittent coronary sinus occlusion in patients with advanced heart failure
title_full_unstemmed Acute molecular effects of pressure‐controlled intermittent coronary sinus occlusion in patients with advanced heart failure
title_short Acute molecular effects of pressure‐controlled intermittent coronary sinus occlusion in patients with advanced heart failure
title_sort acute molecular effects of pressure‐controlled intermittent coronary sinus occlusion in patients with advanced heart failure
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6301157/
https://www.ncbi.nlm.nih.gov/pubmed/30230713
http://dx.doi.org/10.1002/ehf2.12354
work_keys_str_mv AT mohlwerner acutemoleculareffectsofpressurecontrolledintermittentcoronarysinusocclusioninpatientswithadvancedheartfailure
AT spitzerernest acutemoleculareffectsofpressurecontrolledintermittentcoronarysinusocclusioninpatientswithadvancedheartfailure
AT maderrobertm acutemoleculareffectsofpressurecontrolledintermittentcoronarysinusocclusioninpatientswithadvancedheartfailure
AT waghvilas acutemoleculareffectsofpressurecontrolledintermittentcoronarysinusocclusioninpatientswithadvancedheartfailure
AT nguemofilomain acutemoleculareffectsofpressurecontrolledintermittentcoronarysinusocclusioninpatientswithadvancedheartfailure
AT milasinovicdejan acutemoleculareffectsofpressurecontrolledintermittentcoronarysinusocclusioninpatientswithadvancedheartfailure
AT jusicalem acutemoleculareffectsofpressurecontrolledintermittentcoronarysinusocclusioninpatientswithadvancedheartfailure
AT khazencesar acutemoleculareffectsofpressurecontrolledintermittentcoronarysinusocclusioninpatientswithadvancedheartfailure
AT szodoraiedit acutemoleculareffectsofpressurecontrolledintermittentcoronarysinusocclusioninpatientswithadvancedheartfailure
AT birkenbergbeatrice acutemoleculareffectsofpressurecontrolledintermittentcoronarysinusocclusioninpatientswithadvancedheartfailure
AT lubecgert acutemoleculareffectsofpressurecontrolledintermittentcoronarysinusocclusioninpatientswithadvancedheartfailure
AT heschelerjuergen acutemoleculareffectsofpressurecontrolledintermittentcoronarysinusocclusioninpatientswithadvancedheartfailure
AT serruyspatrickw acutemoleculareffectsofpressurecontrolledintermittentcoronarysinusocclusioninpatientswithadvancedheartfailure